← back to search

Claus D. Klemke

Heidelberg University · DE
Area of research
Dermatology · Immunology
Research interest
Research interests include Cutaneous lymphoproliferative disorders research, T-cell and Retrovirus Studies, NF-κB Signaling Pathways, and Lymphoma Diagnosis and Treatment.
h-index
9
citations
373
works
26
NIH funding
primary concept
email

Recent publications

A new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification
Blood 2025cited by 17position: middledoi
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADOReg
European Journal of Cancer 2024cited by 12position: middledoi
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023
European Journal of Cancer 2023cited by 158position: middledoi
S2k‐Guidelines – Cutaneous lymphomas (ICD10 C82 ‐ C86): Update 2021
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2022cited by 48position: middledoi
S2k‐Leitlinie – Kutane Lymphome (ICD10 C82–C86): Update 2021
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2022cited by 29position: middledoi
The optimal use of chlormethine gel for mycosis fungoides: An expert consensus from Germany, Austria and Switzerland (DACH region)
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2022cited by 10position: middledoi
Superior skin cancer classification by the combination of human and artificial intelligence
European Journal of Cancer 2019cited by 352position: middledoi
Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks
European Journal of Cancer 2019cited by 214position: middledoi
Unizentrische, retrospektive Analyse der praktischen Durchführung der extrakorporalen Photopherese
Der Hautarzt 2019cited by 5position: lastdoi
S2k‐Leitlinie – Kutane Lymphome Update 2016 – Teil 2: Therapie und Nachsorge (ICD10 C82 ‐ C86)
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2018cited by 13position: middledoi
Risk factors for surgical site infections are different in patients with cutaneous T cell lymphoma and melanoma
European Journal of Cancer 2018cited by 0position: middledoi
European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
European Journal of Cancer 2017cited by 449position: middledoi
S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 2: Treatment and Follow‐up (ICD10 C82 ‐ C86)
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2017cited by 45position: middledoi
S2k‐Leitlinie – Kutane Lymphome Update 2016 – Teil 1: Klassifikation und Diagnostik (ICD10 C82 ‐ C86)
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2017cited by 27position: middledoi
S2k Guidelines – Cutaneous Lymphomas Update 2016 – Part 1: Classification and Diagnosis (ICD10 C82 ‐ C86)
JDDG Journal der Deutschen Dermatologischen Gesellschaft 2017cited by 18position: middledoi
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib
Oncotarget 2017cited by 14position: middledoi
Evaluation of Immunophenotypic and Molecular Biomarkers for Sézary Syndrome Using Standard Operating Procedures: A Multicenter Study of 59 Patients
Journal of Investigative Dermatology 2016cited by 94position: middledoi
Differential expression of cancer stem cell markers in cutaneous and systemic lymphoma
Experimental Dermatology 2016cited by 1position: lastdoi
Aggressive primary cutaneous B‐cell lymphomas show increased Angiopoietin‐2‐induced angiogenesis
Experimental Dermatology 2015cited by 9position: middledoi
Acid citrate dextrose extracorporeal photopheresis is an alternative treatment option for patients with heparin allergy
International Journal of Dermatology 2015cited by 2position: middledoi
A PP4 Holoenzyme Balances Physiological and Oncogenic Nuclear Factor-Kappa B Signaling in T Lymphocytes
Immunity 2012cited by 55position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jan P. Nicolay · German Cancer Research Center11 papers (2012–2022)Chalid Assaf · Charité - Universitätsmedizin Berlin6 papers (2017–2022) · 6 papers (2015–2022)Rudolf Stadler · Medical University of Vienna5 papers (2017–2018)Edgar Dippel · LMU Klinikum5 papers (2017–2022)Max Schlaak · München Klinik5 papers (2017–2022)Jürgen C. Becker · German Cancer Research Center5 papers (2015–2018)Nina Booken · University Hospital Heidelberg5 papers (2012–2022)Antonio Cozzio · National and Kapodistrian University of Athens5 papers (2017–2018)Dorothée Nashan · Ludwig-Maximilians-Universität München5 papers (2015–2018)Hans Theodor Eich · German Inflammatory Bowel Diseases Study Group4 papers (2017–2018) · 4 papers (2017–2018) · 4 papers (2017–2018)Moritz Felcht · Heidelberg University4 papers (2015–2019)Uwe Hillen · Vivantes Klinikum4 papers (2017–2018)Michael von Bergwelt‐Baildon · Helmholtz Association of German Research Centres4 papers (2017–2018)Marc Beyer · University of Edinburgh4 papers (2017–2018)Tibor Vág · Technical University of Munich4 papers (2017–2018)Michael Weichenthal · Christian-Albrechts-Universität zu Kiel4 papers (2017–2018) · 4 papers (2017–2018)